09:50 AM EST - Crescita Therapeutics Inc. : Reported its financial results for the second quarter ended June 30, 2023. Revenue was $5.1 million, compared to $6.5 million down $1.350 million; Gross profit was just over $3 million compared to $3.647 million, down $578,000. Operating expenses were $3.295 million, compared to $3.447 million, down $152,000. Adjusted EBITDA was $214,000 compared to $646,000, down $432,000. Ending cash was $10,226, down $49 for the quarter. Crescita Therapeutics Inc.
shares T.CTX are trading down $0.03 at $0.70.
